Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
TICLID |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Platelet aggregation inhibitor. |
| Generic Name |
|
Ticlopidine HCl 250mg; tabs. |
| Indications |
|
To reduce the risk of thrombotic stroke in selected patients intolerant of aspirin. |
| Children |
|
Not recommended. |
| Adults |
|
250mg twice daily with food. |
| Contraindications |
|
Hematopoietic disorders including neutropenia, thrombocytopenia, or history of thrombotic thrombocytopenic purpura (TTP). Hemostatic or active bleeding disorders. Severe hepatic impairment. |
| Precautions |
|
Monitor for hematologic toxicity at baseline, every 2 weeks for the first 3 months, and for 2 weeks after discontinuation; test more frequently if signs of hematological changes occur. Discontinue if neutropenia or TTP occur. Renal or hepatic impairment. Bleeding risk (eg, ulcers). Discontinue 10–14 days before surgery. Hyperlipidemia. Pregnancy (Cat.B). Nursing mothers: not recommended. |
| Interactions |
|
Discontinue anticoagulants, fibrinolytics before use. Avoid aspirin. Potentiates aspirin, NSAIDs, anticoagulants, antipyrine, theophylline. Antacids reduce absorption. May be potentiated by cimetidine. Monitor phenytoin. May antagonize digoxin. Caution with propranolol, drugs that increase risk of bleeding, and drugs metabolized by CYP450. |
| Adverse Reactions |
|
Diarrhea, GI upset, rash, neutropenia, pruritus, dizziness, anorexia, abnormal liver function tests, bleeding complications, hyperlipidemia, TTP, aplastic anemia, agranulocytosis, other blood dyscrasis, jaundice. |
| How Supplied |
|
Tabs—30, 60, 500 |
|
|
|
|
